As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.